Difference between revisions of "DDX41"

From Compendium of Cancer Genome Aberrations
Jump to navigation Jump to search
[unchecked revision][unchecked revision]
Line 1: Line 1:
 
==Primary Author(s)*==
 
==Primary Author(s)*==
  
Put your text here
+
Put your text here  
 +
EXAMPLE: Jane Smith, PhD, Institute of Genomics
  
 
__TOC__
 
__TOC__
Line 7: Line 8:
 
==Synonyms==
 
==Synonyms==
  
Put your text here
+
Put your text here  
 
+
EXAMPLE: Tumor protein p53, 'LFS1, p53, BCC7, TRP53
EXAMPLE: Tumor protein p53, ''LFS1, p53, BCC7, TRP53''
 
  
 
==Genomic Location==
 
==Genomic Location==
Line 25: Line 25:
 
==Cancer Category/Type==
 
==Cancer Category/Type==
  
*'''[http://www.ccga.io/index.php/Myeloid_Neoplasms_with_Germline_Predisposition Myeloid Neoplasms with Germline Predisposition]'''
+
Put your text here
 
 
--- '''[http://www.ccga.io/index.php/Myeloid_Neoplasms_with_Germline_DDX41_Mutation Myeloid Neoplasms with Germline DDX41 Mutation]'''
 
  
 
==Gene Overview==
 
==Gene Overview==
Line 35: Line 33:
 
==Common Alteration Types==
 
==Common Alteration Types==
  
Put your text here and/or fill in the table with an X where applicable
+
Put your text here and fill in the table with an X where applicable
  
{| class="wikitable sortable"
+
Copy Number Loss
|-
+
Copy Number Gain
!Copy Number Loss!!Copy Number Gain!!LOH!!Loss-of-Function Mutation!!Gain-of-Function Mutation!!Translocation/Fusion
+
LOH:
|-
+
Loss-of-Function Mutation:
|EXAMPLE: X||EXAMPLE: X||EXAMPLE: X||EXAMPLE: X||EXAMPLE: X||EXAMPLE: X
+
Gain-of-Function Mutation:
|}
+
Translocation/Fusion:
  
 
==Internal Pages==
 
==Internal Pages==
  
'''[[Myeloid Neoplasms with Germline DDX41 Mutation]]'''
+
Put your links here (use "Link" icon at top of page)
 
+
 
==External Links==
 
==External Links==
  
Put your text here - Include as applicable links to: 1) Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2) COSMIC, 3) CIViC, 4) St. Jude ProteinPaint, 5) Precision Medicine Knowledgebase (Weill Cornell), 6) Cancer Index, 7) OncoKB, 8) NCBI Gene 9) My Cancer Genome, 10) UniProt, 11) Pfam, 12) GeneCards, 13) OMIM 14) Leiden Open Variation Database (LOVD(3)) 15) TICdb - database of Translocation breakpoints In Cancer 16) GeneReviews, and 17) Any gene-specific databases.
+
Put your text here - Include as applicable links to:  
 +
1) Atlas of Genetics and Cytogenetics in Oncology and Haematology,  
 +
2) COSMIC,  
 +
3) CIViC,  
 +
4) St. Jude ProteinPaint,  
 +
5) Precision Medicine Knowledgebase (Weill Cornell),  
 +
6) Cancer Index,  
 +
7) OncoKB,  
 +
8) NCBI Gene
 +
9) My Cancer Genome,  
 +
10) UniProt,  
 +
11) Pfam,  
 +
12) GeneCards,  
 +
13) OMIM
 +
14) LOVD(3) - Leiden Open Variation Database
 +
15) TICdb - database of Translocation breakpoints In Cancer
 +
16) GeneReviews, and  
 +
17) Any gene-specific databases.
  
EXAMPLES
+
EXAMPLES (these may be filled in already)
  
 
'''[http://atlasgeneticsoncology.org/Genes/P53ID88.html ''TP53'' by Atlas of Genetics and Cytogenetics in Oncology and Haematology]''' - detailed gene information
 
'''[http://atlasgeneticsoncology.org/Genes/P53ID88.html ''TP53'' by Atlas of Genetics and Cytogenetics in Oncology and Haematology]''' - detailed gene information
Line 82: Line 97:
 
'''[http://www.omim.org/entry/165215 ''MECOM'' by OMIM]''' - compendium of human genes and genetic phenotypes
 
'''[http://www.omim.org/entry/165215 ''MECOM'' by OMIM]''' - compendium of human genes and genetic phenotypes
  
'''[https://databases.lovd.nl/shared/genes/MECOM ''MECOM'' by LOVD(3)]''' - Leiden Open Variation Database
+
'''[https://databases.lovd.nl/shared/genes/MECOM ''MECOM'' by LOVD(3)]''' - Leiden Open Variation Database
  
 
'''[http://www.unav.es/genetica/TICdb/results.php?hgnc=MECOM ''MECOM'' by TICdb]''' - database of Translocation breakpoints In Cancer
 
'''[http://www.unav.es/genetica/TICdb/results.php?hgnc=MECOM ''MECOM'' by TICdb]''' - database of Translocation breakpoints In Cancer
Line 89: Line 104:
  
 
==References==
 
==References==
 
+
(use "Cite" icon at top of page)
 +
<references />
 
===EXAMPLE Book===
 
===EXAMPLE Book===
 +
#Arber DA, et al., (2017). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p129-171.
  
#Arber DA, et al., (2008). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, Editors. IARC Press: Lyon, France, p117-118.
+
=== EXAMPLE Internet Resource ===
 
+
# author name(s).  Date (if possible). page title, website title, web address, and date accessed.
===EXAMPLE Journal Article===
+
# Cingam, S. R. and Koshy, N.V. (2017). Cancer, Leukemia, Promyelocytic, Acute (APL, APML). https://www.ncbi.nlm.nih.gov/books/NBK459352/ Accessed August 3, 2018.
 
 
#Li Y, et al., (2001). Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nat Genet 28:220-221, PMID 11431691.
 
 
 
===EXAMPLE Internet Resource (CMS)===
 
 
 
#author name(s).  Date (if possible). page title, website title, web address, and date accessed.
 
#Cingam, S. R. and Koshy, N.V. (2017). Cancer, Leukemia, Promyelocytic, Acute (APL, APML). https://www.ncbi.nlm.nih.gov/books/NBK459352/ Accessed August 3, 2018.
 
  
==Notes==
+
== Notes ==
 
<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage).  Additional global feedback or concerns are also welcome.
 
<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage).  Additional global feedback or concerns are also welcome.
  
 
[[Category:Cancer Genes D]]
 
[[Category:Cancer Genes D]]

Revision as of 17:27, 7 August 2020

Primary Author(s)*

Put your text here EXAMPLE: Jane Smith, PhD, Institute of Genomics

Synonyms

Put your text here EXAMPLE: Tumor protein p53, 'LFS1, p53, BCC7, TRP53

Genomic Location

Cytoband: Put your text here. EXAMPLE: 17p13.1

Genomic Coordinates:

Put your text here

EXAMPLE: chr17:7,571,720-7,590,868 [hg19]

EXAMPLE: chr17:7,668,402-7,687,538 [hg38]

Cancer Category/Type

Put your text here

Gene Overview

Put your text here.

Common Alteration Types

Put your text here and fill in the table with an X where applicable

Copy Number Loss: Copy Number Gain: LOH: Loss-of-Function Mutation: Gain-of-Function Mutation: Translocation/Fusion:

Internal Pages

Put your links here (use "Link" icon at top of page)

External Links

Put your text here - Include as applicable links to: 1) Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2) COSMIC, 3) CIViC, 4) St. Jude ProteinPaint, 5) Precision Medicine Knowledgebase (Weill Cornell), 6) Cancer Index, 7) OncoKB, 8) NCBI Gene 9) My Cancer Genome, 10) UniProt, 11) Pfam, 12) GeneCards, 13) OMIM 14) LOVD(3) - Leiden Open Variation Database 15) TICdb - database of Translocation breakpoints In Cancer 16) GeneReviews, and 17) Any gene-specific databases.

EXAMPLES (these may be filled in already)

TP53 by Atlas of Genetics and Cytogenetics in Oncology and Haematology - detailed gene information

TP53 by COSMIC - sequence information, expression, catalogue of mutations

TP53 by CIViC - general knowledge and evidence-based variant specific information

TP53 by IARC - TP53 database with reference sequences and mutational landscape

TP53 by St. Jude ProteinPaint mutational landscape and matched expression data.

TP53 by Precision Medicine Knowledgebase (Weill Cornell) - manually vetted interpretations of variants and CNVs

TP53 by Cancer Index - gene, pathway, publication information matched to cancer type

TP53 by OncoKB - mutational landscape, mutation effect, variant classification

MECOM by NCBI Gene - brief gene overview

TP53 by My Cancer Genome - brief gene overview

TP53 by UniProt - protein and molecular structure and function

TP53 by Pfam - gene and protein structure and function information

TP53 by GeneCards - general gene information and summaries

MECOM by OMIM - compendium of human genes and genetic phenotypes

MECOM by LOVD(3) - Leiden Open Variation Database

MECOM by TICdb - database of Translocation breakpoints In Cancer

GeneReviews - information on Li Fraumeni Syndrome

References

(use "Cite" icon at top of page)

EXAMPLE Book

  1. Arber DA, et al., (2017). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p129-171.

EXAMPLE Internet Resource

  1. author name(s). Date (if possible). page title, website title, web address, and date accessed.
  2. Cingam, S. R. and Koshy, N.V. (2017). Cancer, Leukemia, Promyelocytic, Acute (APL, APML). https://www.ncbi.nlm.nih.gov/books/NBK459352/ Accessed August 3, 2018.

Notes

*Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.